RxDoctor Payments Data

Michael Haverty, MD

Family Medicine · Santa Maria, CANPI 1235114729

Payments from drug & device makers

$11,748in general payments, 2019–2025

Across 681 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • GSK$954
  • Pfizer$875
  • Amgen$730
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$11,734100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,748 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$164,441
Medicare patients
503
Services billed
1,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$61,349
JanuviaSitagliptin Phosphate45$59,191
EliquisApixaban39$46,318
JardianceEmpagliflozin38$39,774
FarxigaDapagliflozin Propanediol29$22,417
OzempicSemaglutide16$21,087
Breo ElliptaFluticasone/Vilanterol40$17,801
MyrbetriqMirabegron17$12,639
MounjaroTirzepatide11$12,320
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen253$6,465
BelsomraSuvorexant12$5,191
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$5,070
Memantine Hcl63$4,779
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen55$4,683
Levothyroxine Sodium386$4,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$954$79,151122 claims
MerckJanuvia, Belsomra$208$64,38257 claims
PfizerEliquis$875$46,31839 claims
Boehringer IngelheimJardiance$1,226$39,77438 claims
AstraZenecaFarxiga$1,045$22,41729 claims
Novo NordiskOzempic$1,773$21,08716 claims
Astellas Pharma US IncMyrbetriq$15$12,63917 claims
Lilly USA, LLCMounjaro$720$12,32011 claims
AbbVieSynthroid$730$1,99845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →